IWMW logoIWMW
iShares Russell 2000 BuyWrite ETF

37
Loading...
Loading...
News
all
press releases
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
Craig-Hellum’s price target of $26 represents an upside of about 165% from the stock’s closing price on Thursday.
Stocktwits·7h ago
News Placeholder
More News
News Placeholder
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7.
Stocktwits·1d ago
News Placeholder
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda
The vaccine was approved for initial immunization in individuals aged six years or older and as a booster immunization in those aged 12 years or older in the country.
Stocktwits·1d ago
News Placeholder
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film
The FDA is expected to decide on Aquestive’s application for approval of the sublingual film by January 31, 2026.
Stocktwits·1d ago
News Placeholder
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.
Stocktwits·2d ago
News Placeholder
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate
Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.
Stocktwits·2d ago
News Placeholder
TG Therapeutics Board Authorizes New $100M Share Repurchase Program
The new share repurchase authorization follows the company's completion of its previously authorized $100 million share repurchase program, initially announced in August 2024.
Stocktwits·2d ago
News Placeholder
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.
Stocktwits·3d ago
News Placeholder
Bumble Developing AI-Powered Matchmaking App: Report
According to The Wall Street Journal, the company plans to launch a beta version of the app to select users this fall, which will be separate from the existing Bumble app.
Stocktwits·7d ago
News Placeholder
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.
Stocktwits·8d ago

Latest IWMW News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.